NCT00912535View on ClinicalTrials.gov

Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Primary Anxiety DisordersMood Disorders With Comorbid Anxiety Symptoms
Interventions
DRUG

Quetiapine extended release tablet

Quetiapine extended release tablet of 50-300mg/day

DRUG

Placebo

Placebo orally, as adjunct to the same antidepressant at the same dose.

Trial Locations (1)

Unknown

Chang Gung Memorial Hospital - Keelung, Keelung

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Chang Gung Memorial Hospital

OTHER